Update on recommendations for eligibility of government subsidization of biologic disease-modifying antirheumatic drugs for the treatment of axial spondyloarthritis in Singapore
| Autor: | Teck Choon Tan, K H Leong, Mona Manghani, Anita Yee Nah Lim, Warren Fong, Peter P. Cheung, Manjari Lahiri, Nai Lee Lui, Ying Ying Leung, Gim Gee Teng, Amelia Santosa, Ernest Suresh, Kee Fong Phang, Melonie Kannamma Sriranganathan |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
Consensus Eligibility Determination Disease 03 medical and health sciences 0302 clinical medicine Rheumatology Internal medicine Health care Spondylarthritis medicine Humans 030212 general & internal medicine Axial spondyloarthritis Intensive care medicine Spondylitis Societies Medical 030203 arthritis & rheumatology Government Ankylosing spondylitis Biological Products Singapore business.industry Subsidy medicine.disease Government Programs Antirheumatic Agents business |
| Zdroj: | International journal of rheumatic diseasesREFERENCES. 23(2) |
| ISSN: | 1756-185X |
| Popis: | Aims The field of axial spondyloarthritis (axSpA) has undergone significant changes recently in particular with disease classification, assessment of disease activity and increased treatment options for biologics. In order to reflect these developments, we aimed to update the local consensus recommendations for subsidization of biologics. Methods A modified Delphi approach was used. Six published guidelines from major rheumatology societies and healthcare authorities on axSpA were reviewed. Findings were synthesized and used in formulating updated recommendation statements. Recommendations were rated by 10 practicing rheumatologists in Singapore. Consensus was reached if there was more than 70% agreement or disagreement. Results Ten statements achieved consensus. Patients may be considered for subsidization of biologic therapy if they fulfill the Assessment of Spondyloarthritis International Society or modified New York criteria, with persistently active disease (defined either by Ankylosing Spondylitis Disease Activity Score ≥ 2.1 or Bath Spondylitis Disease Activity Index ≥ 4), despite 4 weeks of full-dose non-steroidal anti-inflammatory drugs and regular exercise. Either tumor necrosis factor inhibitors or interleukin 17 inhibitors may be used as first-line therapy, and should be continued if adequate response is achieved at 6 months. Conclusion Recommendation statements were formulated through a formal consensus process by local experts with a view to assist relevant authorities in funding considerations and for use in clinical practice. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text